1. Home
  2. MLAB vs GLUE Comparison

MLAB vs GLUE Comparison

Compare MLAB & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLAB
  • GLUE
  • Stock Information
  • Founded
  • MLAB 1982
  • GLUE 2019
  • Country
  • MLAB United States
  • GLUE United States
  • Employees
  • MLAB N/A
  • GLUE N/A
  • Industry
  • MLAB Industrial Machinery/Components
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MLAB Industrials
  • GLUE Health Care
  • Exchange
  • MLAB Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • MLAB 341.1M
  • GLUE 308.8M
  • IPO Year
  • MLAB N/A
  • GLUE 2021
  • Fundamental
  • Price
  • MLAB $65.15
  • GLUE $6.36
  • Analyst Decision
  • MLAB Buy
  • GLUE Buy
  • Analyst Count
  • MLAB 2
  • GLUE 2
  • Target Price
  • MLAB $113.50
  • GLUE $13.50
  • AVG Volume (30 Days)
  • MLAB 126.2K
  • GLUE 2.1M
  • Earning Date
  • MLAB 11-06-2025
  • GLUE 11-06-2025
  • Dividend Yield
  • MLAB 0.99%
  • GLUE N/A
  • EPS Growth
  • MLAB N/A
  • GLUE N/A
  • EPS
  • MLAB N/A
  • GLUE 0.29
  • Revenue
  • MLAB $242,351,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • MLAB $5.38
  • GLUE $83.76
  • Revenue Next Year
  • MLAB $5.25
  • GLUE N/A
  • P/E Ratio
  • MLAB N/A
  • GLUE $21.72
  • Revenue Growth
  • MLAB 8.33
  • GLUE 2990.57
  • 52 Week Low
  • MLAB $55.45
  • GLUE $3.50
  • 52 Week High
  • MLAB $155.12
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • MLAB 47.20
  • GLUE 68.06
  • Support Level
  • MLAB $58.83
  • GLUE $4.80
  • Resistance Level
  • MLAB $67.91
  • GLUE $7.44
  • Average True Range (ATR)
  • MLAB 3.73
  • GLUE 0.37
  • MACD
  • MLAB 0.55
  • GLUE 0.21
  • Stochastic Oscillator
  • MLAB 64.16
  • GLUE 61.97

About MLAB Mesa Laboratories Inc.

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: